News of Note—Inovio's MERS vaccine, Inimmune's NIH grant and more

non
(Pixabay)

Here is some other vaccine news of note for the week:

> In a phase 1 study, Inovio and GeneOne Life Science's MERS vaccine, dubbed INO-4700, induced high levels of antibody responses in roughly 95% of subjects and generated broad-based T-cell responses in nearly 90% of study participants. Release

> The University of Montana and startup Inimmune landed a $5.4 million grant from the NIH to develop a vaccine to fight the P. aeruginosa bacteria. Missoula Current article

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

> Allergy Therapeutics’ grass pollen allergy vaccine Pollinex Quattro Grass showed significant and long-lasting symptom improvements three to six years after cessation of treatment. Precision Vaccinations article

 

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.